The clinical assessment of miR-34a and miR-135b panel as promising diagnostic biomarkers predict the risk of colorectal cancer: A case-control study
Cancer Biomarkers · 2026-06 · 43
DOI: 10.1177/18758592261429266 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Cancer Biomarkers, online erschienen am 10.06.2026. Verfasst von Roya Karami und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Hauptthemen laut MEDLINE: MicroRNAs, Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zanjan University of Medical Sciences.
Abstract (Originalsprache)
Background miRNAs are of interest due to have been involved in cancers such as colorectal cancer (CRC).
Objective
To explore the expression levels of miRNA-34a and miRNA-135b and whether they can be potential biomarker for early diagnosis of CRC.
Methods
Fifteen pairs newly diagnosed colorectal cancer and normal involved in the measurement of tissue and serum levels of miRNAs 34a and 135b and their target genes of SIRT1 and DAPK-1. We assessed the predictive value of these miRNAs utilizing the receiver operating characteristic curve.
Results
The findings have shown that the miRNA-34a expression was significantly downregulated and miRNA-135b was upregulated in CRC tissues in comparison to their expression in adjacent normal tissue. This was additionally observed in the serum of the same CRC cases when compared to individuals without CRC. Furthermore, we found a significant increase in the level of SIRT-1 and a significant reduction in the expression level of DAPK-1 in CRC tissues compared to the adjacent normal tissue. The value of AUC was considerably high for the timely detection of CRC.
Conclusions
We found these miRNAs acting as potential non-invasive biomarkers for the early detection of CRC and in assessing the CRC risk within the general population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
- Department of Medical Laboratory, School of Paramedical Sciences, Zanjan University of Medical Sciences, Zanjan, Iran.
- Department of General Surgery, School of Medicine, Ayatollah Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.
- Zanjan Metabolic Diseases Research Center, Health and Metabolic Diseases Research Institute, Zanjan University of Medical Sciences, Zanjan, Iran.
- Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
ORCID-Profile: Hadi Khodabandehloo
Förderung
- Zanjan University of Medical Sciences
Zitieren
APA
Karami, R., Najafi, E., Babaei, A., Shahdoust, E., Shaghaghi, A., Amiri-Dashatan, N., Motlagh, B., Koushki, M., & Khodabandehloo, H. (2026). The clinical assessment of miR-34a and miR-135b panel as promising diagnostic biomarkers predict the risk of colorectal cancer: A case-control study. Cancer Biomarkers, 43. https://doi.org/10.1177/18758592261429266
Vancouver
Karami R, Najafi E, Babaei A, Shahdoust E, Shaghaghi A, Amiri-Dashatan N, et al. The clinical assessment of miR-34a and miR-135b panel as promising diagnostic biomarkers predict the risk of colorectal cancer: A case-control study. Cancer Biomarkers. 2026;43. doi:10.1177/18758592261429266
BibTeX
@article{Karami2026,
author = {Karami, Roya and Najafi, Elaheh and Babaei, Anahita and Shahdoust, Erfan and Shaghaghi, Ali and Amiri-Dashatan, Nasrin and Motlagh, Behrooz and Koushki, Mehdi and Khodabandehloo, Hadi},
title = {The clinical assessment of miR-34a and miR-135b panel as promising diagnostic biomarkers predict the risk of colorectal cancer: A case-control study},
journal = {Cancer Biomarkers},
year = {2026},
volume = {43},
doi = {10.1177/18758592261429266}
}
EUVIMED